1.	Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV01, NCT01465243
2.	First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Phase: Phase IV Type: Treatment Status: Active Age: 70 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV20, NCT01646450
3.	Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV08, NCT01665417
4.	Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV04, NCT01516983
5.	Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: YHH-201201, NCT01534585
6.	Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ZhejiangCH-LCBM-1201, NCT01514877